FDA Phase 2 Approval for Lead Candidate Based on Proprietary Drug Development Platform 'RuCIA', Entering Full-Scale Clinical Trials in 美国
RudaCure Inc. (CEO Yongho Kim), a 生物制药 development company specializing in 感觉障碍 treatments, announced that it has obtained 美国 FDA Phase 2 研究性新药 (IND) approval for its 干眼症治疗药 'RCI001' on the 24th.
RCI001 is a 创新药物候选物 developed using RudaCure's proprietary AI-based 药物开发 platform 'RuCIA (RudaCure Intelligence for Advanced Drug Development).' It has a 作用机制 that suppresses TRPV1 下游信号-mediated 炎症激活 and is differentiated from existing treatments by its powerful 抗炎和抗氧化效果.
RudaCure developed RCI001 through the 'RuCIA' platform, which combines protein structure analysis, molecular dynamics simulation, and AI-based drug design. The company obtained 美国 FDA Phase 2 IND approval within 5 months of completing Phase 1 临床试验, demonstrating the efficiency and innovation of this platform. It is noteworthy that RuCIA achieved this without relying on 'big data AI' requiring massive datasets, instead proving its capability for innovative 新药开发 through a 'small data AI' approach combining structural biology-based simulation with machine learning.
Key results from Phase 1 临床试验 (conducted on 32 subjects at 忠南大学医院 under PI Park Cheol-young) showed no drug-related adverse effects or abnormal findings in vital signs, electrocardiogram, or clinical laboratory tests. Additionally, optimized formulation stability and 眼部 administration suitability were confirmed. While the company's own Phase 1 results are not publicly disclosed as it is a listed company and in an unlisted investment stage, when combined with the 翰林制药-conducted investigator-initiated 临床试验 results (published), it was confirmed that both signs and symptoms (泪液量 increase + 角膜损伤恢复) improved simultaneously, with therapeutic effects appearing rapidly within 4 weeks and no 副作用 of 刺痛, 灼热, or redness upon 滴眼.
RudaCure plans to proceed with Phase 2 临床试验 at major medical institutions in 美国 within 2025, and is simultaneously designing 韩国's Phase 2 临床试验 with plans to begin in the first half of 2026. The company is also pursuing 全球拓展 based on RCI001's 临床数据, including partnering with Thea (法国), Santen (日本), and other global 眼科 制药公司 for licensing and 联合开发, targeting the global 干眼 treatment market projected to exceed $8 billion.
CEO Yongho Kim stated, "The FDA Phase 2 IND approval signifies that RCI001 has been recognized as a candidate with clear potential for innovative 新药开发, and it is a starting point for full-scale 临床试验 in 美国." He added, "Building on these results, we will accelerate global 临床试验 and 技术转让 to provide a new treatment paradigm for the approximately 350 million 干眼 patients worldwide."
